Artiva Biotherapeutics (ARTV) Accumulated Depreciation (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Accumulated Depreciation data on file, last reported at $9.1 million in Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $9.1 million, up 39.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.1 million (up 39.36% YoY), and the FY2025 annual result was $8.5 million, up 42.78% from the prior year.
• Accumulated Depreciation grew to $9.1 million in Q1 2026 per ARTV's latest filing, from $8.5 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $9.1 million in Q1 2026 and troughed at $3.5 million in Q4 2023.
• A 4-year average of $6.7 million and a median of $6.8 million in 2025 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2024 and 2026: Accumulated Depreciation soared 67.7% in 2024, then jumped 39.36% in 2026.
• A 4-year view of Accumulated Depreciation shows it stood at $3.5 million in 2023, then soared by 67.7% to $5.9 million in 2024, then surged by 42.78% to $8.5 million in 2025, then gained by 7.67% to $9.1 million in 2026.
• Business Quant data shows ARTV's Accumulated Depreciation at $9.1 million in Q1 2026, $8.5 million in Q4 2025, and $7.8 million in Q3 2025.